期刊文献+

基于ROC曲线预测华法林治疗患者抗凝强度的研究 被引量:4

Critical value of warfarin initial INR for predicting stable INR using receiver operating characteristic curve
下载PDF
导出
摘要 探讨华法林治疗患者起始国际标准化比值(INR)预测抗凝强度未达标的能力。纳入108例华法林治疗患者,予华法林2.5 mg/d治疗2 d后晨起检测起始INR值,并于服药7 d后重复检测稳态INR值,INR<2定义为抗凝强度未达标。利用受试者工作曲线(ROC curve)检验起始INR值对华法林抗凝治疗未达标的预测效力。利用起始INR值预测华法林治疗抗凝强度未达标的ROC曲线下面积(AUC)为0.872(95%CI=0.772~0.973,P<0.001)。当最佳临界值(CP)为1.145时,预测抗凝强度未达标的敏感性为82.65%,特异性为80%,阳性预测值为97.59%,阴性预测值为32%。通过起始INR值预测华法林抗凝未达标的效力良好,多数华法林治疗患者在使用2.5 mg/d后,如果起始INR值小于1.145,应考虑积极调整华法林剂量。 To evaluate critical value of warfarin initial international normalized radio(INR)for predicting stable INR using receiver operating characteristic curve.A total of 108 patients with warfarin treatment of 2.5 mg/d were enrolled as the subjects,who detected initial INR after two days and detected stable INR after 7 days,INR<2 defined as anticoagulation intensity dissatisfaction.To verify initial INR predicting stable INR using receiver operating characteristic curve.The area under the ROC curve for initial INR to predicting stable INR was 0.872(95%CI:0.772~0.973,P<0.001),when cut point was 1.145,the sensitivity was 82.65%,the specificity was 80%.Positive predictive value was 97.59%,negative predictive value was 32%.Through initial INR value prediction of warfarin anticoagulation effect was good,the majority of patients with warfarin therapy after using of 2.5 mg/d,if the initial INR value is less than 1.145,actively adjust the warfarin dose should be taken into account.
作者 刘小畅 顾智淳 于佳雪 李增 Liu Xiaochang;Gu Zhichun;Yu Jiaxue(Guangdong Provincial People's Hospital Zhuhai Hospital,Zhuhai Golden Bay Center Hospital,Zhuhai 519110;Dept of Pharmacy,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200240)
出处 《安徽医科大学学报》 CAS 北大核心 2019年第8期1323-1325,共3页 Acta Universitatis Medicinalis Anhui
基金 国家自然科学基金青年基金项目(编号:81302701)
关键词 华法林 抗凝 ROC曲线 warfarin anticoagulation ROC curve
  • 相关文献

参考文献1

二级参考文献16

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献588

同被引文献29

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部